Upgrade to SI Premium - Free Trial

Bristol-Myers Squibb Co. (BMY) PT Raised to $68 at BofA/Merrill Lynch on Increased Confidence of Opdivo/Yervoy Approvability

March 5, 2018 9:19 AM
BofA/Merrill Lynch raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $68.00 (from $64.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles